Evidence map›Paper›PMID 38535587›Full record

ArticlePathogens (Basel, Switzerland)2024

Indoor Inactivation of SARS-CoV-2 Virus by Liquid Hyperoxygen.

Giovanni Barco, Zumama Khalid, Alessandra Pulliero, Claudio Angelinetta, Ubaldo Prati, Alberto Izzotti

Open access · goldAbstract read
In one paragraph

Article in Pathogens (Basel, Switzerland), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 95% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Giovanni BarcoIstituto Internazionale Barco SpA, 56121 Pisa, Italy.
Zumama KhalidDepartment of Health Sciences, University of Genoa, 16132 Genoa, Italy.
Alessandra PullieroDepartment of Health Sciences, University of Genoa, 16132 Genoa, Italy.ORCID 0000-0001-5378-9517
Claudio AngelinettaBiobasic Europe Laboratory, 20146 Milano, Italy.
Ubaldo PratiIstituto Internazionale Barco SpA, 56121 Pisa, Italy.
Alberto IzzottiDepartment of Experimental Medicine, University of Genoa, 16132 Genoa, Italy.ORCID 0000-0002-8588-0347
Istituto Nazionale di Fisica Nucleare, Sezione di Milano Bicocca · ITUniversity of Genoa · ITOspedale Policlinico San Martino · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The possible future emergence of new SARS-CoV-2 virus variants pushes the development of new chemoprophylaxis protocols complementary to the unspecific and specific immune-prophylaxis measures currently used. The SARS-CoV-2 virus is particularly sensitive to oxidation, due to the relevant positive electrical charge of its spike protein used as a ligand for target cells. The present study evaluated the safety and efficacy of a new oxidant preparation, liquid hyperoxygen (IOL), to neutralize the SARS-CoV-2 virus. IOL was incubated with throat swabs containing a human-type virus. The samples were then incubated with cells expressing the ACE2 receptor and, therefore, very sensitive to SARS-CoV-2 infection. The ability to neutralize SARS-CoV-2 was determined by assessing the amount of viral nucleic acid inside cells by PCR. The results obtained indicate that IOL, even at considerable dilutions, is capable, after incubation times of less than 30 min and even equal to 5 min, of completely inhibiting SARS-CoV-2 infection. This inhibitory effect has been shown to be due to the oxidizing capacity of the IOL. This oxidizing capacity is exerted towards the virus but does not damage eukaryotic cells either in the in vitro or in vivo skin models. Obtained results indicate that the use of IOL, a hydrophilic liquid mixture saturated with highly reactive oxygen and nitrogen species, is a new powerful, safe, and effective tool for preventing possible future outbreaks of the COVID-19 disease.

Indexed as

COVID-19SARS-CoV-2AnimalsChlorocebus aethiopsHumansOxidantsVirus InactivationOxidantsCOVID-19 infectionenvironmental disinfectionoxidative curepreventionSARS-CoV-2 virus

Identifiers

PMID38535587
PMCPMC10974922
OpenAlexW4392709607

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.